The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study

Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Oct 18, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment for preventing tuberculosis (TB) in patients who have received a kidney transplant. Kidney transplant recipients are at a higher risk of developing TB due to their immune systems being weakened by medication. The study is looking at whether a shorter treatment plan using rifamycin-containing medications is safe and effective for these patients. Specifically, it will compare these treatments to longer options that have been used in the general population.

To be eligible for the study, participants must be at least 20 years old, have received a kidney transplant, and agree to undergo a test to check for latent TB infection (LTBI). If the test shows they have LTBI, they can choose to participate in the trial and receive treatment. The trial is currently recruiting participants, and those who join can expect regular check-ups to monitor their health and how well the treatment is working. It’s important to note that pregnant individuals or those with signs of active TB will not be included in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Received kidney transplant, and
• • 2. Will receive interferon-gamma release assay (IGRA) for LTBI, and
• • 3. If IGRA was positive, participants agree to receive LTBI treatment
• Exclusion Criteria:
• • 1. Age \< 20 years old
• • 2. pregnancy
• • 3. Suspicious active tuberculosis